News & Events

For Immediate Release

Bookmark & Share
Contact: Kathryn Ryan, 914-740-2100, kryan@liebertpub.com
Study Links Hypoxemia From Obstructive Sleep Apnea With Renal Complications in Type 2 Diabetes
New Rochelle, NY, April 22, 2016—Examining the poorly understood link between obstructive sleep apnea (OSA) and type 2 diabetes complications, researchers identified specific measures of low blood oxygenation that are associated with impaired kidney function and diabetic nephropathy. The study by Linong Ji, MD and colleagues, Peking University People's Hospital and Peking University Health Science Center (Beijing, China), is published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website until May 22, 2016.
 
 In the article “Association of Diabetic Microvascular Complications and Parameters of Obstructive Sleep Apnea in Patients with Type 2 Diabetes,” the researchers describe the use of overnight sleep monitoring with measurement of respiratory parameters including the apnea hyponea index, oxygen desaturation index, oxygen saturation, and the total time oxygen saturation was below 90% or 85%. They report which parameters of nocturnal hypoxemia were more closely linked to diabetic microvascular complications such as renal disease.
 
“Adequate sleep has been a topic of discussion recently, and this study highlights the association of sleep apnea with microvascular disease associated with diabetes,” says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver. “To some extent this finding may be associated with obesity, which is a common occurrence with type 2 diabetes.”
 
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.
 
About ATTD
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
 
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.